Barclays PLC Acquires Shares of 11,479 Delcath Systems, Inc. (NASDAQ:DCTH)

Barclays PLC acquired a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) in the third quarter, HoldingsChannel.com reports. The firm acquired 11,479 shares of the company’s stock, valued at approximately $104,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Geode Capital Management LLC increased its stake in Delcath Systems by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock valued at $2,275,000 after purchasing an additional 7,298 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Delcath Systems during the 3rd quarter valued at about $110,000. State Street Corp boosted its holdings in shares of Delcath Systems by 12.4% during the 3rd quarter. State Street Corp now owns 85,457 shares of the company’s stock valued at $772,000 after acquiring an additional 9,400 shares during the last quarter. Polar Asset Management Partners Inc. purchased a new stake in shares of Delcath Systems during the 3rd quarter valued at about $1,594,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Delcath Systems during the 3rd quarter valued at about $102,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Trading Up 6.0 %

DCTH opened at $16.13 on Friday. The company has a market cap of $515.68 million, a price-to-earnings ratio of -11.95 and a beta of 0.87. The company’s 50 day moving average is $11.79 and its 200 day moving average is $10.08. Delcath Systems, Inc. has a 12-month low of $3.70 and a 12-month high of $16.34.

Analyst Upgrades and Downgrades

DCTH has been the topic of a number of recent analyst reports. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Craig Hallum raised their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a report on Tuesday, January 14th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a report on Friday, October 18th. Finally, Stephens reissued a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.25.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.